Table 1 Baseline characteristics.

From: Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study

 

Gecacitinib

HU

(n = 71)

(n = 34)

Age, years

63.5 (8.02)

62.1 (10.19)

Gender—male

29 (40.8%)

15 (44.1%)

ECOG performance status

 0

20 (28.2%)

8 (23.5%)

 1

47 (66.2%)

26 (76.5%)

 2

4 (5.6%)

0

Disease subtype

 PMF

50 (70.4%)

27 (79.4%)

 Post-PV-MF

9 (12.7%)

3 (8.8%)

 Post-ET-MF

12 (16.9%)

4 (11.8%)

Prior HU therapy

30 (42.3%)

17 (50.0%)

Prior JAK inhibitors

1 (1.4%)

2 (5.9%)

MF grading

 MF-0

0

2 (5.9%)

 MF-1

2 (2.8%)

2 (5.9%)

 MF-2

27 (38.0%)

14 (41.2%)

 MF-3

42 (59.2%)

15 (44.1%)

 NA

0

1 (2.9%)

DIPSS risk status

 Intermediate-2

63 (88.7%)

31 (91.2%)

 High

8 (11.3%)

3 (8.8%)

MF duration, years

1.5 (2.54)

1.3 (2.36)

Spleen volume by MRI/CT, cm3

1514.8 (820.79)

1549.7 (734.75)

MPN-SAF TSS

21.2 (14.54)

21.4 (14.43)

Mutations

 JAK2 V617F

42 (59.2%)

20 (58.8%)

 CALR

19 (26.8%)

9 (26.5%)

  TYPE-1

8 (11.3%)

6 (17.6%)

  TYPE-2

6 (8.5%)

1 (2.9%)

  Others

5 (7.0%)

2 (5.9%)

 MPL W515L/K

4 (5.6%)

4 (11.8%)

WBC, 109/L

20.6 (17.5)

24.6 (21.1)

HGB, g/L

97.1 (27.5)

96.8 (24.7)

HGB < 100 g/L

47 (66.2)

22 (64.7)

PLT, 109/L

349.7 (267.7)

407.2 (372.2)

RBC transfusion dependency

6 (8.5%)

3 (8.8%)

  1. Data presented as mean (SD) or n (%).
  2. ECOG Eastern Cooperative Oncology Group, DIPSS dynamic international prognostic scoring system, TSS total symptom score, WBC white blood cell count, HGB hemoglobin level, PLT platelet count.
Back to article page